CN103145679B - 表没食子儿茶素没食子酸酯的制备方法及其用途 - Google Patents
表没食子儿茶素没食子酸酯的制备方法及其用途 Download PDFInfo
- Publication number
- CN103145679B CN103145679B CN201310065322.XA CN201310065322A CN103145679B CN 103145679 B CN103145679 B CN 103145679B CN 201310065322 A CN201310065322 A CN 201310065322A CN 103145679 B CN103145679 B CN 103145679B
- Authority
- CN
- China
- Prior art keywords
- green tea
- epigallocatechin gallate
- anemia
- water
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title claims abstract description 121
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 115
- 229940030275 epigallocatechin gallate Drugs 0.000 title claims abstract description 113
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 73
- 244000269722 Thea sinensis Species 0.000 claims abstract description 49
- 235000009569 green tea Nutrition 0.000 claims abstract description 31
- 229940094952 green tea extract Drugs 0.000 claims abstract description 31
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 25
- 208000007502 anemia Diseases 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000000287 crude extract Substances 0.000 claims abstract description 20
- 238000000605 extraction Methods 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 28
- 239000011347 resin Substances 0.000 claims description 28
- 229920005989 resin Polymers 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 19
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 18
- 208000007475 hemolytic anemia Diseases 0.000 claims description 16
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 13
- 208000002903 Thalassemia Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000001953 recrystallisation Methods 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 claims description 2
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract 2
- 210000003743 erythrocyte Anatomy 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 26
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 22
- 235000013616 tea Nutrition 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 125000004403 catechin group Chemical group 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 125000004402 polyphenol group Chemical group 0.000 description 12
- 150000008442 polyphenolic compounds Chemical class 0.000 description 11
- 235000013824 polyphenols Nutrition 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 10
- 235000005487 catechin Nutrition 0.000 description 10
- 229950001002 cianidanol Drugs 0.000 description 10
- 239000011259 mixed solution Substances 0.000 description 10
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 9
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 9
- 235000012734 epicatechin Nutrition 0.000 description 9
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 9
- 210000003013 erythroid precursor cell Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 230000003394 haemopoietic effect Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108060003196 globin Proteins 0.000 description 3
- 230000036449 good health Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 102000018146 globin Human genes 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000567 anti-anemic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- -1 catechin compound Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000001907 heinz body Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 动物数(只) | RBC(×1012/L) | Hb(g/L) |
空白对照组 | 20 | 8.85±0.76 | 136.7±8.7 |
模型对照组 | 20 | 6.11±0.57** | 100.7±7.9** |
EGCG组 | 20 | 8.48±0.74▲ | 128.4±7.7▲▲ |
儿茶素组 | 20 | 7.87±0.69▲ | 120.7±9.9▲ |
表儿茶素组 | 20 | 7.48±0.74▲ | 109.6±8.4 |
茶多酚组 | 20 | 7.86±0.57▲ | 107.8±11.7 |
组别 | 动物数(只) | RBC(×1012/L) | Hb(g/L) |
空白对照组 | 20 | 8.27±0.67 | 124.1±9.4 |
模型对照组 | 20 | 7.11±0.58* | 101.5±7.8** |
硫酸亚铁片组(阳性对照) | 20 | 8.04±0.55▲ | 118.6±8.6▲▲ |
EGCG组 | 20 | 8.24±0.60▲ | 121.7±9.8▲▲ |
儿茶素组 | 20 | 7.99±0.63▲ | 106.4±8.5 |
表儿茶素组 | 20 | 7.86±0.84▲ | 108.7±7.9 |
茶多酚组 | 20 | 7.79±0.70▲ | 104.1±10.8 |
组别 | 动物数(只) | WBC(×109/L) | Hb(g/L) | RBC(×1012/L) | PLT(×109/L) |
空白对照组 | 20 | 13.86±4.60 | 139.0±20 | 9.01±1.03 | 1597±298 |
模型对照组 | 20 | 5.93±1.86* | 108.1±15* | 6.54±0.97* | 891±204* |
EGCG组 | 20 | 12.39±2.94▲ | 132.2±18▲ | 8.84±0.88▲ | 1530±211▲ |
儿茶素组 | 20 | 11.29±3.28▲ | 118.6±15▲ | 6.41±1.01* | 1301±198▲ |
表儿茶素组 | 20 | 8.38±2.38▲ | 110.4±10* | 7.09±0.86* | 1025±230* |
茶多酚组 | 20 | 10.57±2.67▲ | 114.6±13* | 7.15±0.98▲ | 964±246* |
Claims (11)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310065322.XA CN103145679B (zh) | 2013-02-28 | 2013-02-28 | 表没食子儿茶素没食子酸酯的制备方法及其用途 |
PCT/CN2013/072763 WO2014131213A1 (zh) | 2013-02-28 | 2013-03-15 | 表没食子儿茶素没食子酸酯的制备方法及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310065322.XA CN103145679B (zh) | 2013-02-28 | 2013-02-28 | 表没食子儿茶素没食子酸酯的制备方法及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103145679A CN103145679A (zh) | 2013-06-12 |
CN103145679B true CN103145679B (zh) | 2015-04-29 |
Family
ID=48544057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310065322.XA Active CN103145679B (zh) | 2013-02-28 | 2013-02-28 | 表没食子儿茶素没食子酸酯的制备方法及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103145679B (zh) |
WO (1) | WO2014131213A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105995802A (zh) * | 2016-05-20 | 2016-10-12 | 孙勇 | 一种理气除烦紫米果酱及其制备方法 |
CN106220597A (zh) * | 2016-07-21 | 2016-12-14 | 范瑶飞 | 一种化合物及其制备方法 |
US11110145B2 (en) | 2017-09-25 | 2021-09-07 | Amorepacific Corporation | Composition for protecting cell from oxidative stress comprising green tea extract which has modified amounts of ingredients |
KR20190048502A (ko) * | 2017-10-31 | 2019-05-09 | (주)아모레퍼시픽 | 성분 함량이 변화된 차 추출물을 포함하는 순환기 질환 개선용 조성물 |
CN107721967A (zh) * | 2017-11-20 | 2018-02-23 | 浙江天草生物科技股份有限公司 | 一种高egcg含量的绿茶提取物生产工艺 |
JP2019147772A (ja) * | 2018-02-28 | 2019-09-05 | サッポロホールディングス株式会社 | ヘプシジン発現抑制剤、並びに鉄欠乏性貧血改善及び/又は予防用飲食品 |
CN109589323A (zh) * | 2018-12-11 | 2019-04-09 | 福州乾正药业有限公司 | 神经酸与egcg的固体分散体组合物及其制备方法和应用 |
CN112684191A (zh) * | 2020-12-04 | 2021-04-20 | 上海润普生物技术有限公司 | 一种ABO血型正反定型及Rh血型检测卡及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01175978A (ja) * | 1987-12-29 | 1989-07-12 | Itouen:Kk | 粗カテキン化合物製造方法 |
CN1752082A (zh) * | 2005-08-12 | 2006-03-29 | 上海诺德生物实业有限公司 | 一种没食子酸酯儿茶素及它的制备方法 |
CN101643466A (zh) * | 2009-06-02 | 2010-02-10 | 江苏天晟药业有限公司 | 一种高纯度的表没食子儿茶素没食子酸酯及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1316243A (zh) * | 2000-04-03 | 2001-10-10 | 陈建操 | 茶多酚及其氧化物治疗贫血症的新用途 |
-
2013
- 2013-02-28 CN CN201310065322.XA patent/CN103145679B/zh active Active
- 2013-03-15 WO PCT/CN2013/072763 patent/WO2014131213A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01175978A (ja) * | 1987-12-29 | 1989-07-12 | Itouen:Kk | 粗カテキン化合物製造方法 |
CN1752082A (zh) * | 2005-08-12 | 2006-03-29 | 上海诺德生物实业有限公司 | 一种没食子酸酯儿茶素及它的制备方法 |
CN101643466A (zh) * | 2009-06-02 | 2010-02-10 | 江苏天晟药业有限公司 | 一种高纯度的表没食子儿茶素没食子酸酯及其制备方法 |
Non-Patent Citations (3)
Title |
---|
聚酰胺色谱法分离制备高纯度表没食子儿茶素没食子酸酯;王传金 等;《应用化学》;20070430;第24卷(第4期);第443-447页 * |
血管内皮细胞功能及儿茶素干预机制的研究;庞爱明;《医药卫生科技辑》;20061115(第11期);E065-72 第45页 * |
表没食子儿茶素没食子酸酯的研究进展;仉燕崃 等;《中草药》;20060228;第37卷(第2期);第303-306页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103145679A (zh) | 2013-06-12 |
WO2014131213A1 (zh) | 2014-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103145679B (zh) | 表没食子儿茶素没食子酸酯的制备方法及其用途 | |
KR101512495B1 (ko) | 혈구 감소 관련 질환 예방 및 치료용 약물을 제조하기 위한 악티게닌의 용도 | |
CN103768534B (zh) | 一种具有抗肿瘤活性的中药组合物 | |
KR101977840B1 (ko) | 백혈병 치료용 약학 조성물 및 그 제조 방법 | |
CN103768152A (zh) | 桂花苯乙醇苷提取物及其制备方法和用途 | |
CN101099753A (zh) | 救必应总皂苷的制备方法及应用 | |
CN106822166B (zh) | 一种防治糖尿病和高脂血症的药物及其在制药中的应用 | |
CN101224246B (zh) | 一种枇杷叶总三萜酸的制备方法及其降血糖功能 | |
CN101444599B (zh) | 玉米须提取物及其制备方法和在制备治疗痛风药物中的应用 | |
CN104857180B (zh) | 抗疲劳及提高免疫力的组合物及其制备方法和应用 | |
CN101467967B (zh) | 用于静脉和脑内注射的两元溶液型制剂 | |
CN101273990A (zh) | 赫替新型二萜生物碱在制备治疗或预防房颤药物中的应用 | |
CN103006789A (zh) | 贞芪缓释制剂的制备方法及产品 | |
CN103830374B (zh) | 三叶糖脂清在高尿酸血症中的应用 | |
CN105106300A (zh) | 青钱柳提取物在制备防治非酒精性脂肪肝的药物中的应用 | |
US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
CN113116867B (zh) | 一种预防和/或治疗流感的组合物 | |
CN109966283B (zh) | 脱脂肉桂多酚提取物在制备防治糖尿病肾病产品中的应用 | |
CN101157689A (zh) | 一种水飞蓟宾和苦参素或苦参碱的复盐及其应用 | |
CN101032534A (zh) | 救必应总皂苷的制备方法及应用 | |
CN110101802A (zh) | 一种治疗高血压的药物组合物 | |
KR101320486B1 (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 항암 치료보조제 조성물 | |
CN113116869B (zh) | 一种预防和/或治疗抑郁的组合物 | |
CN100525759C (zh) | 一种用于治疗缺血性脑血管疾病的中成药 | |
CN110585250B (zh) | 长白落叶松树根总黄酮在抑制尿酸升高和预防治疗痛风疾病中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 430075 666 hi tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei Patentee after: WUHAN HUADA PHARMACEUTICAL Co.,Ltd. Patentee after: BGI SHENZHEN Co.,Ltd. Patentee after: BGI WUHAN Co.,Ltd. Address before: 430075 666 hi tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei Patentee before: Wuhan Huada Pharmaceutical Co.,Ltd. Patentee before: BGI DIAGNOSIS Co.,Ltd. Patentee before: BGI WUHAN Co.,Ltd. Address after: 430075 666 hi tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei Patentee after: WUHAN HUADA PHARMACEUTICAL Co.,Ltd. Patentee after: BGI DIAGNOSIS Co.,Ltd. Patentee after: BGI WUHAN Co.,Ltd. Address before: 430075 666 hi tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei Patentee before: Wuhan Huada Pharmaceutical Co.,Ltd. Patentee before: BGI HEALTH SERVICE Co.,Ltd. Patentee before: BGI WUHAN Co.,Ltd. |